Dose comparison of conivaptan (Vaprisol(®)) in patients with euvolemic or hypervolemic hyponatremia – efficacy, safety, and pharmacokinetics

PURPOSE: This study aimed to evaluate the efficacy, safety, and pharmacokinetics of 20 and 40 mg/day conivaptan (Vaprisol(®)) in patients with hypervolemic or euvolemic hyponatremia. METHODS: Hyponatremic patients – serum sodium (sNa) ≤130 mEq/L – received either 20 or 40 mg/day of conivaptan for 4...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug Des Devel Ther
Hauptverfasser: Palmer, Biff F, Rock, Amy D, Woodward, Emily J
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove Medical Press 2016
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4723016/
https://ncbi.nlm.nih.gov/pubmed/26848258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S95326
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge